CVM Cel Sci Corp

Price (delayed)

$4.51

Market cap

$195.59M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.85

Enterprise value

$183.21M

CEL-SCI believes that boosting a patient’s immune system while it is still intact should provide the greatest possible impact on survival. Therefore, in the Phase 3 study CEL-SCI treated patients ...

Highlights
CVM's debt is up by 2.9% year-on-year but it is down by 2.2% since the previous quarter
The company's revenue has shrunk by 100% YoY
The gross profit has plunged by 100% YoY

Key stats

What are the main financial stats of CVM
Market
Shares outstanding
43.37M
Market cap
$195.59M
Enterprise value
$183.21M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.05
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$35M
EBITDA
-$31.57M
Free cash flow
-$19.14M
Per share
EPS
-$0.85
Free cash flow per share
-$0.44
Book value per share
$0.89
Revenue per share
$0
TBVPS
$1.31
Balance sheet
Total assets
$56.89M
Total liabilities
$18.16M
Debt
$15.69M
Equity
$38.73M
Working capital
$26.94M
Liquidity
Debt to equity
0.41
Current ratio
7.71
Quick ratio
6.99
Net debt/EBITDA
0.39
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-55.1%
Return on equity
-76.6%
Return on invested capital
-79.7%
Return on capital employed
-66.2%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CVM stock price

How has the Cel Sci stock price performed over time
Intraday
-2.38%
1 week
15.94%
1 month
17.45%
1 year
-52.33%
YTD
-36.48%
QTD
0.22%

Financial performance

How have Cel Sci's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$35.59M
Net income
-$36.74M
Gross margin
N/A
Net margin
N/A
The company's revenue has shrunk by 100% YoY
The gross profit has plunged by 100% YoY
CVM's net income is down by 8% year-on-year and by 2% since the previous quarter
Cel Sci's operating income has increased by 4.7% from the previous quarter

Growth

What is Cel Sci's growth rate over time

Valuation

What is Cel Sci stock price valuation
P/E
N/A
P/B
5.05
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The stock's price to book (P/B) is 100% less than its 5-year quarterly average of 6544.9 and 13% less than its last 4 quarters average of 5.8
The equity has decreased by 35% YoY and by 14% from the previous quarter
The company's revenue has shrunk by 100% YoY

Efficiency

How efficient is Cel Sci business performance
CVM's return on equity is up by 22% year-on-year but it is down by 13% since the previous quarter
The return on assets has grown by 11% year-on-year but it has declined by 11% since the previous quarter
Cel Sci's return on invested capital has decreased by 7% QoQ

Dividends

What is CVM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CVM.

Financial health

How did Cel Sci financials performed over time
The total assets has contracted by 29% YoY and by 11% from the previous quarter
Cel Sci's quick ratio has decreased by 27% YoY and by 9% from the previous quarter
CVM's debt is 59% smaller than its equity
The company's debt to equity has surged by 58% YoY and by 14% QoQ
The equity has decreased by 35% YoY and by 14% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.